EMA says disclosure policy 'will not impinge on IP rights'
This article was originally published in SRA
Executive Summary
The European Medicines Agency's new policy on clinical trial data disclosure will ensure transparency in the interests of public health without impinging on a company's intellectual property rights1. So says the agency in publishing the final advice from its five cross-sector groups that have been looking at the scientific, technical, legal and ethical issues surrounding this vexed and controversial topic.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.